HIGHLIGHTS
- who: F. Coussy from the France France France France have published the research work: Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers, in the Journal: (JOURNAL)
- what: The aim of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. The authors report here the establishment and molecular characterization of MBC PDXs. The authors show, for the first time, that a combination of PI3K and MEK inhibitors is highly effective against MBC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.